Research Title: A randomized sham-controlled double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kallikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema (ciDME) who have had prior anti-vascular endothelial growth factor (VEGF) treatment.
Sponsor: KalVista Pharmaceticals, Ltd.
Principal Investigator: Robert Stoltz, M.D., Ph.D
Description: The purpose of this study is to evaluate the efficacy, safety, and tolerability of KVD001 Injection as monotherapy in adult subjects with ciDME who have had prior anti-VEGF treatment.
Start Date: Spring 2017
Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, CCRC, COA
Location(s): Marietta; 833 Campbell Hill Street, Suite 300, Marietta, GA 30060